S
Sonia Jangra
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 35
Citations - 1172
Sonia Jangra is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Immune system & Medicine. The author has an hindex of 8, co-authored 21 publications receiving 394 citations. Previous affiliations of Sonia Jangra include Mount Sinai Health System.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 spike E484K mutation reduces antibody neutralisation.
Sonia Jangra,Chengjin Ye,Raveen Rathnasinghe,Daniel Stadlbauer,Florian Krammer,Viviana Simon,Luis Martinez-Sobrido,Adolfo García-Sastre,Michael Schotsaert +8 more
Journal ArticleDOI
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.
Kris M. White,Romel Rosales,Soner Yildiz,Thomas Kehrer,Lisa Miorin,Elena Moreno,Sonia Jangra,Melissa B. Uccellini,Raveen Rathnasinghe,Lynda Coughlan,Carles Martínez-Romero,Jyoti Batra,Ajda Rojc,Mehdi Bouhaddou,Jacqueline M. Fabius,Kirsten Obernier,Marion Dejosez,Maria Jose Guillen,Alejandro Losada,Pablo Aviles,Michael Schotsaert,Thomas P. Zwaka,Marco Vignuzzi,Kevan M. Shokat,Nevan J. Krogan,Adolfo García-Sastre +25 more
TL;DR: In this article, the authors showed that plitidepsin (aplidin) possesses antiviral activity (90% inhibitory concentration = 0.88 nM) that is more potent than remdesivir against SARS-CoV-2 in vitro by a factor of 27.5.
Journal ArticleDOI
Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2.
Tia A. Tummino,Veronica V. Rezelj,Benoit Fischer,Audrey Fischer,Matthew J. O’Meara,Blandine Monel,Thomas Vallet,Kris M. White,Ziyang Zhang,Assaf Alon,Heiko Schadt,Henry R. O’Donnell,Jiankun Lyu,Romel Rosales,Briana L. McGovern,Raveen Rathnasinghe,Sonia Jangra,Michael Schotsaert,Jean-Rene Galarneau,Nevan J. Krogan,Laszlo Urban,Kevan M. Shokat,Andrew C. Kruse,Adolfo García-Sastre,Olivier Schwartz,Francesca Moretti,Marco Vignuzzi,Francois Pognan,Brian K. Shoichet +28 more
TL;DR: For example, this paper found that phospholipidosis was a shared mechanism underlying the antiviral activity of many repurposed drugs, including hydroxychloroquine, azithromycin, amiodarone, and four others already in clinical trials.
Posted ContentDOI
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
Sonia Jangra,Chengjin Ye,Raveen Rathnasinghe,Daniel Stadlbauer,Florian Krammer,Viviana Simon,Luis Martinez-Sobrido,Adolfo García-Sastre,Michael Schotsaert +8 more
TL;DR: In this article, the E484K mutation in the spike RBD was found to leave vaccinees less protected against newly emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Posted ContentDOI
The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera
Raveen Rathnasinghe,Sonia Jangra,Anastasija Cupic,Carles Martínez-Romero,Lubbertus C. F. Mulder,Thomas Kehrer,Soner Yildiz,Angela Choi,Ignacio Mena,Jana De Vrieze,Sadaf Aslam,Daniel Stadlbauer,David A. Meekins,Chester McDowell,Velmurugan Balaraman,Juergen A. Richt,Bruno G. De Geest,Lisa Miorin,Florian Krammer,Viviana Simon,Adolfo García-Sastre,Michael Schotsaert +21 more
TL;DR: In this paper, a mouse-adapted SARS-CoV-2 was serial passed through a clinical virus isolate in the lungs of mice and then used low doses of this virus in mouse models for advanced age, diabetes and obesity.